Disposable Endoscopes Market: as FDA regulatory pressure on duodenoscope reprocessing converges with published clinical evidence on cost, performance, and emissions, single-use endoscopy is expanding beyond its bronchoscopy and duodenoscopy origins into urology, ENT, and gastrointestinal applications, so category conversion is compounding across new clinical indications faster than the underlying procedure volume alone would predict.

The global disposable endoscopes market size was USD 1.52 Billion in 2025 and is expected to register a revenue CAGR of 17.5% during the forecast period.Market revenue growth is driven by factors such as sustained FDA regulatory pressure on reusable duodenoscope reprocessing, published clinical evidence demonstrating cost, performance, and environmental advantages for single-use instruments, and category expansion beyond bronchoscopy and duodenoscopy into urology, ENT, and gastrointestinal applications.The first driving factor is sustained FDA regulatory pressure on reusable duodenoscope reprocessing following documented carbapenem-resistant Enterobacteriaceae outbreak investigations linked to elevator channel contamination.The FDA published updated reprocessing guidance for flexible duodenoscopes reinforcing single-use as the preferred design approach where elevator channel contamination risk cannot be eliminated through reprocessing protocols alone.The second driving factor is published clinical evidence demonstrating single-use endoscope advantages across cost, performance, and environmental dimensions simultaneously.A 2024 study documented 13% lower cost per single-use bronchoscopy procedure versus reusable bronchoscopes, while a separate lifecycle assessment documented 20% lower CO2 emissions for single-use cystoscopes including sterilisation energy consumption.The third driving factor is the expansion of single-use endoscopy into clinical indications beyond its original bronchoscopy and duodenoscopy base.In June 2025, Ambu A/S received FDA 510(k) clearance for its aScope 5 Cysto HD as the first-ever single-use cysto-nephroscope approved for percutaneous nephrolithotomy procedures, establishing a new product category within disposable endoscopy.These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single-use endoscope platform widens its addressable revenue every time it earns clearance for a new clinical indication on the same underlying instrument architecture, without the manufacturer having to build an entirely new product line from zero.Once a manufacturer establishes a single-use endoscopy platform and display system in one clinical area, extending the same core architecture into a new procedure type adds incremental procedure volume without a new capital equipment sale, so platform revenue compounds as the indication list grows around the original display unit.As a result, demand and revenue share are concentrating around platforms with the broadest clinical indication range built on a shared display and processing architecture, that hold the deepest published clinical evidence base, and the forecast tilts toward these multi-indication ecosystems rather than single-procedure disposable scopes.For instance, in September 2025, Olympus Corporation announced a global distribution agreement with MacroLux Medical Technology for single-use urology products including ureteroscopes, cystoscopes, and suction access sheaths, extending an established reusable endoscopy incumbent's commercial reach into the single-use category without the multi-year internal development cycle a ground-up product line would require.These are some of the key factors driving revenue growth of the market.

Because single-use medical device waste volumes and disposal costs create procurement barriers at Nordic, German, and UK NHS health systems with formal sustainability and carbon accounting requirements, hospitals in these markets face institutional pressure to justify single-use conversion against environmental criteria.

Per-procedure cost is a second constraint, since single-use endoscopes ranging from USD 35 to USD 800 depending on type exceed reprocessed reusable equivalent costs at high-volume centres with well-established sterile processing infrastructure.

Chinese domestic manufacturer competition is a third constraint, as Hunan Vathin and Scivita Medical Technology introduce lower-cost single-use alternatives that trigger volume-based procurement in Asian markets, compressing average selling prices and limiting premium brand pricing power for Ambu and Boston Scientific.

These factors substantially limit disposable endoscopes market growth over the forecast period.

The clearest driver of demand is sustained FDA regulatory pressure on reusable duodenoscope reprocessing following documented infection outbreaks. A reprocessing guideline only converts into single-use adoption if the underlying clinical risk cannot be engineered away, and the FDA's own post-market surveillance data confirms elevator channel contamination persists even under strengthened reprocessing protocols, so the regulatory rationale for single-use duodenoscopes has strengthened rather than faded over time. The Joint Commission revised its 2024 standards to mandate real-time tracking of every high-level disinfection cycle, requiring mid-size endoscopy suites to invest over USD 50,000 in cycle-tracking hardware, shortening the payback period on single-use endoscopes to as little as 12 months at high-volume centres. Dedicated CPT codes for single-use endoscopes introduced in 2023 resolved payment ambiguity and improved outpatient margins by up to 20%, and in January 2025 Pentax Medical launched its ONE Pulmo single-use bronchoscope in Europe, joining Ambu aScope and Karl Storz Slimline C-MAC as primary commercial platforms at European hospital formularies. The effect on the market is that both the clinical risk case and the reimbursement infrastructure for single-use duodenoscopes and bronchoscopes are now mutually reinforcing rather than independently developing. These are some of the key factors driving revenue growth of the market.

The second driver is the accumulation of published clinical evidence addressing the three primary procurement objections to single-use endoscopes: cost, performance, and environmental impact simultaneously. A procurement committee only approves single-use conversion at scale once independent published evidence, not just manufacturer marketing claims, addresses all three objections together, and 2024 peer-reviewed studies did exactly that for bronchoscopy and cystoscopy. A 2024 study documented 13% lower cost per single-use bronchoscopy procedure versus reusable bronchoscopes at a high-volume hospital, and a separate 2024 lifecycle assessment documented 20% lower CO2 emissions for single-use cystoscopes including sterilisation energy consumption. In April 2025, KARL STORZ launched its Slimline C-MAC S single-use video laryngoscope, and in June 2025 Ambu received FDA 510(k) clearance for its aScope 5 Cysto HD, the first single-use cysto-nephroscope cleared for percutaneous nephrolithotomy procedures. The effect on the market is that hospital formulary committees now have a defensible, multi-dimensional evidence base to approve single-use conversion beyond the ICU bronchoscopy setting where the category first achieved adoption. These are some of the key factors driving revenue growth of the market.

“Ambu's aScope 5 Cysto HD became the first single-use cysto-nephroscope cleared for percutaneous nephrolithotomy, a procedure category that had no cleared single-use option before June 2025.”

However, the disposable endoscopes market faces severe adoption constraints from environmental sustainability concerns, per-procedure cost disadvantages, and Chinese domestic manufacturer price competition.

Because single-use medical device plastic waste volumes and disposal costs create procurement barriers at Nordic, German, and UK NHS health systems with formal sustainability requirements, manufacturers must now address carbon accounting objections alongside clinical and cost arguments.

Verathon introduced a GlideScope Spectrum QC eco single-use laryngoscope manufactured from 80% bio-based plastics, addressing sustainability objections but at higher material cost, illustrating that environmental compliance and cost competitiveness currently pull in opposite directions for manufacturers.

Chinese domestic manufacturer competition is the third constraint, as Hunan Vathin and Scivita Medical Technology trigger price competition that compresses average selling prices in Asian volume-based procurement tenders, limiting pricing power for Ambu and Boston Scientific in price-sensitive markets.

These factors substantially limit disposable endoscopes market growth over the forecast period.

Based on product type, the global disposable endoscopes market is segmented into single-use bronchoscopes, single-use duodenoscopes, single-use ureteroscopes and cystoscopes, and single-use GI and ENT endoscopes. Single-use bronchoscopes account for the largest revenue share at approximately 37% of 2025 market revenue. Ambu A/S established the clinical and commercial template for the single-use bronchoscope category through its aScope product family, reporting that its Endoscopy Solutions business posted 15.4% organic growth in FY2024/25. Single-use ureteroscopes and cystoscopes are expected to register the fastest revenue growth rate over the forecast period, driven by Ambu's June 2025 FDA clearance for the aScope 5 Cysto HD as the first single-use cysto-nephroscope cleared for PCNL procedures.

Based on regional analysis, the disposable endoscopes market in North America accounted for the largest revenue share in 2025. The United States is the dominant contributor through FDA regulatory pressure on reusable duodenoscope reprocessing, the 2023 dedicated CPT code introduction, and the commercial presence of Ambu A/S's US distribution headquarters and Boston Scientific's EXALT platform. Ambu A/S's FY2024/25 Annual Report cited that outpatient facilities in the US accounted for 54% of North American disposable endoscope revenue, reflecting rapid ASC channel adoption of single-use scopes. The concentration of FDA clearances for new single-use indications in the United States also means new product categories are often launched in the United States first.

The market in Europe is expected to register the fastest revenue growth rate of all regional markets in the global disposable endoscopes market over the forecast period.

Germany, the United Kingdom, France, and Scandinavia represent the four largest national disposable endoscopes markets within Europe. Pentax Medical launched its ONE Pulmo single-use bronchoscope in Europe in January 2025, joining Ambu aScope and Karl Storz Slimline C-MAC as the primary commercial single-use endoscope platforms at European hospital formularies. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have raised costs for specialty polymer and imaging sensor components used in European single-use endoscope manufacturing, a disruption that has run through 2026 and affects manufacturers with China and Mexico production facilities.

The market in Asia Pacific is expected to register a rapid revenue growth rate in the global disposable endoscopes market over the forecast period.

China, Japan, South Korea, and Australia represent the four largest national disposable endoscopes markets within the region. China's provincial tenders include disposable scopes to meet infection control targets under National Health Commission directives, favouring local manufacturers including Hunan Vathin that avoid import duties relative to international brands. In September 2025, Olympus Corporation announced a global distribution agreement with MacroLux Medical Technology for single-use urology products, extending an established reusable endoscopy incumbent's reach into the single-use category and signalling accelerating competitive entry into the region's fastest-growing procedure segment.

The market in Latin America is expected to register a moderate revenue growth rate in the global disposable endoscopes market over the forecast period.

Brazil and Mexico represent the two largest national disposable endoscopes markets within the region, with access to single-use endoscopy concentrated at private hospital networks with formal infection control programmes. Iran-US sanctions and their indirect effect on Strait of Hormuz shipping have maintained elevated import costs for single-use endoscope components entering Brazilian and Mexican distribution networks, a disruption that has run through 2026.

The market in Middle East and Africa is expected to register a moderate revenue growth rate in the global disposable endoscopes market over the forecast period.

Saudi Arabia and the United Arab Emirates represent the primary commercial markets within the GCC. Saudi Arabia is the most established market on the continent for single-use endoscope adoption, supported by the Vision 2030 healthcare investment programme, while the wider Gulf and North African sub-regions are still building the basic endoscopy infrastructure single-use conversion assumes is already in place.